AEXCID Cooperación Extreña (11IA002), and coordinated in the Iberoamerican Network of Pharmacogenetics (SIFF).

Disclosure of Interest: None declared.

PP149—THE CEIBA COCKTAIL FOR DRUG HYDROXYLATION PHENOTYPING IN HISPANIC POPULATIONS

F. De Andrés1; M.E.G. Naranjo1; M. Sosa-Macias2; B.P. Lazalde Ramos3; E. Tarazona-Santos4; A. LLerena3,4; and CEIBA Consortium

1CICAB, Clinical Research Centre, Extremadura University Hospital, BADAJOZ, Spain; 2Centro Interdisciplinario de Investigación para el Desarrollo Integral Regional of the IPN Unidad Durango, CIIDIR-IPN, Durango; 3Laboratorio de Medicina Molecular, Unidad Académica de Medicina Humana y Ciencias de la Salud, Universidad Autónoma de Zacatecas, Zacatecas, Mexico; and 4Departamento de Biología Geral, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

Introduction: Interethnic variability of drug metabolism has been demonstrated across Iberoamerican populations by the CEIBA Consortium. Drug-metabolizing enzymes genotype just predicts actual drug metabolic activity (phenotype) in the cases of poor metabolizers. For example, only 30% of ultrarapid metabolizers can be predicted from genotyping (Llerena et al., 2012). Moreover, according to EMA recommendations, development of phenotyping procedures for drug interactions studies and clinical research recommended (EMA, 2013). Therefore, a novel cocktail approach to measure metabolic activity (metabolic ratios) of the main CYP enzymes in just one experiment is developed and validated to be used in the study of Latin-American populations.

Patients (or Materials) and Methods: Subjects were given low oral doses of 100-mg caffeine, 25-mg losartan, 20-mg oxemtrazol, and 30-mg dextromethorphan. Blood samples were taken 4 hours after administering the drugs to assay the following metabolic ratios in plasma: CYP1A2 (caffeine/paraxanthine), CYP2C9 (losartan /E-3174), CYP2C19 (omeprazole/5-hydroxyomeprazole), CYP2C6 (dextromethorphan/dextorphan), and CYP3A4 (dextromethorphan/3-methyloxymethphinan). Solid phase extraction was utilized for analyte extraction and LC-MS/MS to quantify the probe drugs and metabolites.

Results: Recovery values > 80% were obtained for all analytes, and no carryover or relative matrix effects were observed. The analytes were separated and detected in 9 minutes and the method was fully validated, with lower limits of quantification ranging from 0.3 ng/mL-1 for 5-hydroxymeprazole to 3.2 ng/mL-1 for paraxanthine. The correlation coefficient (r2) values obtained were over 0.995 for all analytes. According to the EMA guideline on bioanalytical method validation, precision and accuracy values below 15% were achieved.

Conclusion: The method was proven to be useful to measure targeted analytes for the evaluation of CYPs hydroxylation capacity in just a single experiment.

Funding Sources: Supported by AEXCID-Cooperación Extreña of Junta de Extremadura (11IA002) to Sociedad Ibero-Americana de Farmacogenética-SIFF, and coordinated by the RIBEF network (Red Iberoamericana de Farmacogenética y Farmacogenómica; www.ribef.com).

Disclosure of Interest: None declared.

PP151—PREVALENCE OF CARRIAGE CYP2C9, VKORC1 AND CYP4F2 POLYMORPHISMS IN RUSSIAN PATIENTS WITH HIGH THROMBOTIC RISK PRESCRIBED WARFARIN COMPARED WITH OTHER ETHNIC GROUPS

D. Ivashchenkova1; D. Sychev1; I. Rusin1; A. Grachev1; and T. Beloshickaya1

1Clinical Pharmacology, I.M. Sechenov First Moscow State Medical University; 2Cardiology; and 3Medical Genetic, SM-Clinic, Moscow, Russian Federation

Introduction: VKORC1, CYP2C9, and CYP4F2 responsible for the metabolism of warfarin. Personal and ethnic differences in the genetic profile reveals in determining the outcome of a drug therapy. Aim: to explore the frequencies of CYP2C9, VKORC1, and CYP4F2 genotypes in Russians, compare results with ones for other nations.

Patients (or Materials) and Methods: A total 91 Caucasian subjects were recruited into the study. Forty (48.2%) patients were male and age was 66,17 (10.9) years. All patients had indications to receive warfarin. Medical records for the patients group were reviewed for the relevant clinical data. 5 ml of blood was taken from each subject, and DNA was isolated and used for identification of the CYP2C9 allele *1, *2, *3; G-1639A VKORC1; CYP4F2 V433M rs2108622 C > T using real-time polymerase chain reaction-restriction fragment length polymorphism assay. Results were compared with other ethnic groups and statistically analyzed with chi-square test.

Results: We described the prevalence of CYP2C9 polymorphisms *1/*1 (67%), *1/*2 (9,9%), *1/*3 (11%), *2/*2 (2,2%), *2/*3 (8,8%), same for VKORC1 GG (49,5%), GA (28,6%), AA (22%), and CYP4F2 CC (57,1%), CT (34,1%), TT (7,7%). No significant deviations from Hardy-Weinberg equilibrium were observed (p < 0.05). Polymorphisms’ frequency of CYP2C9 (P < 0.001) and VKORC1 GG, AA (P < 0.05) in Russian distinguish from Asian. There are no significant interethnic variations for CYP4F2 between Russian, Asian and Caucasian (P > 0.05).

Conclusion: Prevalence of carriage of CYP2C9, VKORC1 polymorphisms in Russian patients with high thrombotic risk is closed to Caucasians and distinguish from Asians but no for CYP4F2.

Disclosure of Interest: None declared.

PP152—TENDENCY TO HIGHER ACTIVITY OF CYP3A5 IN WOMEN WITH STILLBIRTH

K. Zagarodnikova1; M. Kondrahina1; J. Rustanovich1; and D. Kostyuchek: St Petersburg, Russian Federation

Introduction: CYP3A5 is an enzyme known to be involved in metabolism of human hormones – progesterone and testosterone, which metabolism may play a role in either disease origin or treatment efficacy in women with stillbirth. There is a common genetic polymorphism leading to its increased activity (CYP3A5*3, CYP3A5*1, CYP3A5*1). Our aim was to investigate possible role of this polymorphism in stillbirth.

Patients (or Materials) and Methods: All women admitted to gynecology department of university clinics with verified diagnoses of stillbirth were considered for recruitment to the study. At the same time women who attended routine pregnancy registration were screened and recruited at the same time as the study group being matched by their age and concomitant diseases. All women who gave informed consent were recruited. Peripheral venous blood samples were drawn into EDTA tubes. DNA was extracted. Polymerase chain reaction in real time was performed to detect genetic variants of CYP3A5 (*3/*1 (6986 A>G). Chi-square test was used for frequency comparisons using statistical software Graphpad Prizm 5.0.

Results: Fifty-three women with stillbirth were recruited to the study. Control group consisted of 92 matched women. Frequency of the minor
allele A in the study group was 8%, in the control group – 4% (p = 0.1; chi-square). The following genotypes distribution was observed in the study group: AA – 0.02; AG – 0.13; GG – 0.85. In the control group the following genotype distribution was observed: AA – 0.01; AG – 0.05; GG – 0.94. Distributions corresponded to Hardy-Weinberg equilibrium.

**Conclusion:** In our prospective study, we observed tendency to genetic predisposition to higher activity of CYP3A5 in women with stillbirth compared with matched women with normal pregnancy. The results, however, did not reach statistical significance, which may demonstrate either lack of real association or insufficient number of subjects recruited.

The observation needs to be proved or disproved in a larger population.

**Disclosure of Interest:** None declared.

---

**PP153—EVALUATION OF THE RELATIONSHIPS BETWEEN ABCB1 C3435T AND G2677T/A POLYMORPHISMS AND CLINICAL RESPONSE TO VENLAFAXINE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER**

G. Oz bey1; F. Cam Celikel2; B. Elbozan Cumurcu3; D. Kan5; B. Yuel5; E. Hasbek2; F. Percin4; and C. Uluoglu6

1Pharmacology, Akdeniz University Medical Faculty, Antalya; 2Psychiatry, Gaziosmanpasa University Medical Faculty, Tokat; 3Psychiatry, Inonu University Medical Faculty, Malatya; 4Genetics, Gazi University Medical Faculty, Ankara; 5Pharmacology, Local Health Authority, Izmir; and 6Pharmacology, Gazi University Medical Faculty, Ankara, Turkey

**Introduction:** Venlafaxine, as a substrate of p-glycoprotein, is a widely used serotonin-noradrenaline reuptake inhibitor (SNRI). The aim of the study is to investigate the influence of ABCB1 G2677T/A, C3435T polymorphisms on efficacy of venlafaxine.

**Patients (or Materials) and Methods:** Patients (n = 52) who met the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-IV criteria for major depressive disorder (MDD) were enrolled in the study. All patients had affirmed for once a day administration of venlafaxine at 8:00 to 9:00 AM during the study. Protocol visits were completed at baseline, 1st, 2nd, 4th, and 6th weeks. The clinical response to venlafaxine was evaluated by psychiatrists through an iterative process.

**Results:** Our results showed that there is no correlation between efficacy of venlafaxine and ABCB1 G2677T/A, C3435T polymorphisms. Results were analyzed by PCR/RFLP assays. The following genotypes distribution was observed: AA (21.36 ± 0.695), AG (22.45 ± 2.077), and GG (21.78 ± 0.737). In the control group the following genotypes distribution was observed: AA (21.64 ± 1.865), AG (17.63 ± 2.195), and GG (15.34 ± 0.852). The difference was significant (P = 0.672).

**Table:** HAMD_17 scores according to ABCB1 G2677T/A, C3435T genotypes.

<table>
<thead>
<tr>
<th></th>
<th>3435C&gt;T</th>
<th>2677G&gt;TA</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>CC-CT</td>
<td>TT</td>
</tr>
<tr>
<td>HAMD &lt;sub&gt;17&lt;/sub&gt; baseline</td>
<td>21.56 ± 0.695</td>
<td>22.45 ± 2.077</td>
</tr>
<tr>
<td>HAMD &lt;sub&gt;17&lt;/sub&gt; 1st week</td>
<td>14.93 ± 0.851</td>
<td>16.73 ± 2.195</td>
</tr>
<tr>
<td>HAMD &lt;sub&gt;17&lt;/sub&gt; 2nd week</td>
<td>13.76 ± 0.939</td>
<td>15.64 ± 1.820</td>
</tr>
<tr>
<td>HAMD &lt;sub&gt;17&lt;/sub&gt; 4th week</td>
<td>11.27 ± 0.668</td>
<td>11.54 ± 1.883</td>
</tr>
<tr>
<td>HAMD &lt;sub&gt;17&lt;/sub&gt; 6th week</td>
<td>9.63 ± 1.11</td>
<td>10.09 ± 2.095</td>
</tr>
</tbody>
</table>

**Conclusion:** Although our results showed that there is no correlation between efficacy of venlafaxine and ABCB1 G2677T/A, C3435T polymorphisms, we couldn’t reach the sufficient patient number. There is need for studies with sufficient patient number and haplotype analysis including also ABCB1 C1236T polymorphism in MDD patients.

**Disclosure of Interest:** G. Oz bey: No conflict to declare. F. Cam Celikel: No conflict to declare. B. Elbozan Cumurcu: No conflict to declare. D. Kan: No conflict to declare. B. Yuel: No conflict to declare. E. Hasbek: No conflict to declare. F. Percin: No conflict to declare. C. Uluoglu: No conflict to declare.

---

**PP154—PERSONALISING HEALTH CARE: FEASIBILITY AND FUTURE IMPLICATIONS FOR ALL STAKEHOLDER GROUPS INCLUDING AUTHORITIES, PHYSICIANS AND PATIENTS**

B. Godman1,2; A.E. Finlayson1; P. Cheema4; E. Zebedin-Brandl1,2; I. Gutiérrez-Ibarluzea7; E. Diogene8; K. Paterson9; V. Vlahovic-Palcevski10; and L.L. Gustafsson1

1Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 2Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow; 4INDOX, Research Network, Oxford University, Oxford, United Kingdom; 3Sunnybrook Odette Cancer Centre, Toronto, Canada; 7Osteba Basque Office for HTA, Ministry of Health of the Basque Country, Bilbao; 9Unitat de Coordinació i Estratègia del Medicament, Direcció Adjunta d’Afers Assistencials, Catalan Institute of Health, Barcelona, Spain; 10Unit for Clinical Pharmacology, University Hospital Rijeka, Rijeka, Croatia

**Introduction:** The promise of personalized care has not always translated into improvements in patient care. There are concerns among payers that advice for certain genetic tests has been revoked, diagnostic tests can be costly, and there is fragmentation of funding for care including tests. In addition, pharmaceutical companies are seeking high prices for new targeted drugs through designating them as orphan drugs. Consequently, there is a need to integrate current knowledge about the value of genetic, biomarkers, prognostic tests and targeted drug therapies from a health authority perspective to provide future guidance.

**Patients (or Materials) and Methods:** This will be achieved by (1) reviewing the current literature regarding personalized medicine; (2) appraising key funding, organizational, and health care issues as orphan drugs. Consequently, there is a need to integrate current knowledge about the value of genetic, biomarkers, prognostic tests and targeted drug therapies from a health authority perspective to provide future guidance.

**Patients (or Materials) and Methods:** This will be achieved by (1) reviewing the current literature regarding personalized medicine; (2) appraising key funding, organizational, and health care issues as orphan drugs. Consequently, there is a need to integrate current knowledge about the value of genetic, biomarkers, prognostic tests and targeted drug therapies from a health authority perspective to provide future guidance.

**Results:** Multiple findings are consolidated under headings. These include (1) general considerations incorporating definitions and the need for different approaches to progress personalized medicine; (2) knowledge about the influence of pharmacogenomics on response and toxicity of drug therapies using current examples including cases where recommendations have recently been revoked; (3) knowledge of the value of biomarker tests to target treatment approaches; (4) challenges and concerns including the potentially high cost of tests and targeted therapies and current fragmentation of funding; and (5) key issues for health care funding bodies to address to enhance funding for new diagnostic/prognostic tests as well as new targeted therapies. Guidance is given on potential ways forward for all key stakeholder groups including reviewing key medical, ethical, legal,